- Home
- COEP vs ELEV Comparison
COEP vs ELEV Comparison
Compare COEP & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- ELEV
- Stock Information
- Founded
- COEP 2017
- ELEV 2019
- Country
- COEP United States
- ELEV United States
- Employees
- COEP N/A
- ELEV N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- ELEV Health Care
- Exchange
- COEP Nasdaq
- ELEV Nasdaq
- Market Cap
- COEP 32.4M
- ELEV 37.6M
- IPO Year
- COEP N/A
- ELEV 2021
- Fundamental
- Price
- COEP $10.52
- ELEV $0.61
- Analyst Decision
- COEP
- ELEV Buy
- Analyst Count
- COEP 0
- ELEV 6
- Target Price
- COEP N/A
- ELEV $7.20
- AVG Volume (30 Days)
- COEP 109.2K
- ELEV 1.3M
- Earning Date
- COEP 03-25-2025
- ELEV 03-05-2025
- Dividend Yield
- COEP N/A
- ELEV N/A
- EPS Growth
- COEP N/A
- ELEV N/A
- EPS
- COEP N/A
- ELEV N/A
- Revenue
- COEP N/A
- ELEV N/A
- Revenue This Year
- COEP N/A
- ELEV N/A
- Revenue Next Year
- COEP N/A
- ELEV N/A
- P/E Ratio
- COEP N/A
- ELEV N/A
- Revenue Growth
- COEP N/A
- ELEV N/A
- 52 Week Low
- COEP $2.31
- ELEV $0.50
- 52 Week High
- COEP $13.70
- ELEV $5.83
- Technical
- Relative Strength Index (RSI)
- COEP 48.65
- ELEV 43.44
- Support Level
- COEP $9.27
- ELEV $0.64
- Resistance Level
- COEP $12.95
- ELEV $0.72
- Average True Range (ATR)
- COEP 1.59
- ELEV 0.05
- MACD
- COEP -0.33
- ELEV -0.00
- Stochastic Oscillator
- COEP 38.56
- ELEV 18.41
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.